Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (161-170 of 387) with videos related to

Pageof 39
Sort By:
Haematologica|July 9, 2016
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planesAnita Kumar, Irene A Burger, Zhigang Zhang, et al.
Haematologica|December 7, 2005
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trialDavid Dingli, S Vincent Rajkumar, Grzegorz S Nowakowski, et al.
Blood|January 5, 2002
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphomaStephen M Ansell, Thomas E Witzig, Paul J Kurtin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 16, 2002
Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemiaJames R Cerhan, Celine M Vachon, Thomas M Habermann, et al.
Hematological Oncology|March 7, 2026
Anatomical Localization-Based Analysis of Relapsed Secondary Central Nervous System Aggressive B-Cell Lymphoma (R-SCNSL)Izel Okcu, Yucai Wang, Zhuo Li, et al.
Gastroenterology|September 6, 2006
Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patientsFrank A Sinicrope, Rafaela L Rego, Kevin C Halling, et al.
American Journal of Hematology|June 8, 2012
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patientsStephen M Ansell, Matthew J Maurer, Steven C Ziesmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2005
Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment GroupThomas E Witzig, Allen M Vukov, Thomas M Habermann, et al.
Blood|October 1, 2024
High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutationsZhuoer Xie, Jenna Fernandez, Terra Lasho, et al.
Leukemia & Lymphoma|September 27, 2019
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?Mattia Novo, Grzegorz S Nowakowski, Thomas M Habermann, et al.
Pageof 39

Showing results (161-170 of 387) with videos related to

Sort By:
Pageof 39
Haematologica|July 9, 2016
Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planesAnita Kumar, Irene A Burger, Zhigang Zhang, et al.
Haematologica|December 7, 2005
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trialDavid Dingli, S Vincent Rajkumar, Grzegorz S Nowakowski, et al.
Blood|January 5, 2002
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphomaStephen M Ansell, Thomas E Witzig, Paul J Kurtin, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 16, 2002
Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemiaJames R Cerhan, Celine M Vachon, Thomas M Habermann, et al.
Hematological Oncology|March 7, 2026
Anatomical Localization-Based Analysis of Relapsed Secondary Central Nervous System Aggressive B-Cell Lymphoma (R-SCNSL)Izel Okcu, Yucai Wang, Zhuo Li, et al.
Gastroenterology|September 6, 2006
Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patientsFrank A Sinicrope, Rafaela L Rego, Kevin C Halling, et al.
American Journal of Hematology|June 8, 2012
Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patientsStephen M Ansell, Matthew J Maurer, Steven C Ziesmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2005
Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment GroupThomas E Witzig, Allen M Vukov, Thomas M Habermann, et al.
Blood|October 1, 2024
High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutationsZhuoer Xie, Jenna Fernandez, Terra Lasho, et al.
Leukemia & Lymphoma|September 27, 2019
Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?Mattia Novo, Grzegorz S Nowakowski, Thomas M Habermann, et al.
Pageof 39